2-(6-bromohexyl)naphthalene | 210056-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(6-bromohexyl)naphthalene
• 英文别名: 2-(6-Brom-hexyl)-naphthalin；6-(2-naphthyl)hexyl bromide
• CAS: 210056-83-0
• 化学式: C₁₆H₁₉Br
• 分子量: 291.231
• InChiKey: PAVAGTANAFUCPY-UHFFFAOYSA-N

物化性质

• 沸点：
  150-152 °C(Press: 0.5 Torr)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-(6-bromohexyl)naphthalene 在 potassium cyanide 作用下， 生成 7-[2]萘基-庚腈
  参考文献：
  名称：

  Huisgen; Rietz, Chemische Berichte, 1957, vol. 90, p. 2768,2777

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 platinum(IV) oxide N-溴代丁二酰亚胺(NBS) 、 氢气 、 二异丁基氢化铝 、 dimsyl sodium 、 三苯基膦 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 2.42h， 生成 2-(6-bromohexyl)naphthalene
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• SUBSTITUTED PROPIONYL DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0949238A1

  公开（公告）日：1999-10-13

  The present invention relates to a compound represented by the following formula (1): [wherein, X1 represents a carboxyl group which may be esterified or the like group; Y1 represents a single bond, -O- or -N(R1)-; at least one of A1, A2 and A3 is a group represented by the following formula (2): -R2-a1-R3-a2 →wherein, R2 represents a divalent C2-12 hydrocarbon group, R3 represents a single bond or a divalent C1-12 hydrocarbon group, a1 and a2 individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, -N(R4)-, -CON(R5)-, -C(=O)- or - Si(R6)(R7)- and → means bonding with Q1, Q2 or Q3}, the remaining one or two of A1, A2 and A3 are the same or different and each independently represents a group represented by the following formula (3): -R8-a3-R9-a4 →wherein, R8 and R9 individually represent a single bond or a divalent C1-12 hydrocarbon group, a3 and a4 individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, - N(R10)-, -CON(R11)-, -C(=O)- or -SI(R12)(R13)- and → means bonding with Q1, Q2 or Q3},; at least one of Q1, Q2 and Q3 represents a cyclic hydrocarbon group or heterocyclic group and the remaining one or two of Q1, Q2 and Q3 individually represent a hydrogen atom, a carboxyl group which may be esterified, a hydrocarbon group or a heterocyclic group] or salt thereof; and a pharmaceutical comprising the same as an effective ingredient. The compound exhibits strong squalene synthetase inhibitory action and is therefore useful as a pharmaceutical for the treatment·prevention of hypercholesterolemia, hyperlipemia or arteriosclerosis.

  本发明涉及一种由以下式（1）表示的化合物：[其中，X1代表可能酯化或类似基团的羧基；Y1代表单键，-O-或-N（R1）-；A1、A2和A3中至少有一个是由以下式（2）表示的基团：-R2-a1-R3-a2 →其中，R2代表二价的C2-12碳氢基团，R3代表单键或二价的C1-12碳氢基团，a1和a2分别代表单键，-S-，-SO-，-SO2-，-SO2NH-，-O-，-N（R4）-，-CON（R5）-，-C（=O）-或-Si（R6）（R7）-，→表示与Q1、Q2或Q3结合}，A1、A2和A3中剩余的一个或两个是相同或不同的，并且每个独立地表示由以下式（3）表示的基团：-R8-a3-R9-a4 →其中，R8和R9分别代表单键或二价的C1-12碳氢基团，a3和a4分别代表单键，-S-，-SO-，-SO2-，-SO2NH-，-O-，-N（R10）-，-CON（R11）-，-C（=O）-或-SI（R12）（R13）-，→表示与Q1、Q2或Q3结合}；Q1、Q2和Q3中至少有一个代表环烃基或杂环烃基，剩余的一个或两个分别代表氢原子，可能酯化的羧基，碳氢基团或杂环烃基的其中一个或两个]或其盐；以及包括其作为有效成分的药物。该化合物表现出强烈的角鲨烯合酶抑制作用，因此可用作治疗高胆固醇血症、高脂血症或动脉硬化的药物。
• Tuning the Antibacterial Activity of Amphiphilic Neamine Derivatives and Comparison to Paromamine Homologues
  作者：Louis Zimmermann、Antoine Bussière、Myriam Ouberai、Isabelle Baussanne、Claude Jolivalt、Marie-Paule Mingeot-Leclercq、Jean-Luc Décout

  DOI：10.1021/jm401148j

  日期：2013.10.10

  dialkyl derivatives of the small aminoglycoside neamine active against susceptible and resistant Gram-positive and Gram-negative bacteria. One of these derivatives (R = 2-naphthylpropyl), which has good activity against MRSA and VRSA, showed a low toxicity in eukaryotic cells at 10 μM. The synthesis of amphiphilic paromamine and neamine homologous derivatives pointed out the role of the 6′-amine function

  氨基糖苷是通过与rRNA结合起作用的抗生素药物。在寻找针对细菌膜的抗菌两亲性氨基糖苷类药物时，我们在这里报告了发现了对敏感和耐药革兰氏阳性和革兰氏阴性细菌有活性的小氨基糖苷神经酰胺的三种二烷基衍生物的发现。这些衍生物之一（R = 2-萘丙基）具有良好的抗MRSA和VRSA活性，在10μM的真核细胞中显示出低毒性。两亲性巴胺和神经胺同源衍生物的合成指出了神经胺核心的6'-胺功能在抗菌作用中的作用。附着于神经胺核上的亲脂取代基的最佳数目和此处确定的相应所需亲脂性应允许相对于真核膜更具选择性地靶向细菌膜。这项工作揭示了亲脂性窗口的存在，该窗口是获得强大的抗菌作用所必需的，这在抗菌的两亲性氨基糖苷类领域应引起人们的兴趣。
• Huisgen; Rietz, Chemische Berichte, 1957, vol. 80, p. 2768,2778
  作者：Huisgen、Rietz

  DOI：——

  日期：——
• ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme
  作者：Andrew D. Gribble、Roland E. Dolle、Antony Shaw、David McNair、Riccardo Novelli、Christine E. Novelli、Brian P. Slingsby、Virendra P. Shah、David Tew、Barbara A. Saxty、Mark Allen、Pieter H. Groot、Nigel Pearce、John Yates

  DOI：10.1021/jm960167w

  日期：1996.1.1

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.
• Huisgen; Rietz, Chemische Berichte, 1957, vol. 90, p. 2768,2777
  作者：Huisgen、Rietz

  DOI：——

  日期：——